CR20190127A - Métodos para detectar aav - Google Patents

Métodos para detectar aav

Info

Publication number
CR20190127A
CR20190127A CR20190127A CR20190127A CR20190127A CR 20190127 A CR20190127 A CR 20190127A CR 20190127 A CR20190127 A CR 20190127A CR 20190127 A CR20190127 A CR 20190127A CR 20190127 A CR20190127 A CR 20190127A
Authority
CR
Costa Rica
Prior art keywords
determining
particles
aav
heterogeneity
methods
Prior art date
Application number
CR20190127A
Other languages
English (en)
Inventor
Catherine R O´Riordan
Lin Liu
Xiaoying Jin
Kate Zhang
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59762045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20190127(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CR20190127A publication Critical patent/CR20190127A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/04—Preparation or injection of sample to be analysed
    • G01N30/06—Preparation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/075—Adenoviridae

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Photoreceptors In Electrophotography (AREA)

Abstract

En la presente memoria se proporcionan métodos para determinar el serotipo de una partícula de virus y/o para determinar la heterogeneidad de una partícula de virus (p. ej., una partícula de AAV). En otras realizaciones, la invención proporciona métodos para determinar la heterogeneidad de partículas de AAV. En algunos aspectos, la invención proporciona partículas virales (p. ej., partículas de AAVr) con estabilidad mejorada y/o eficiencia de la transducción mejorada mediante el incremento de la acetilación y/o desamidación de las proteínas de la cápsideProvided herein are methods for determining the serotype of a virus particle and/or or determining the heterogeneity of a virus particle (e.g., an AAV particle). In other embodiments, the invention provides methods to determine the heterogeneity of AAV particles. In some aspects, the invention provides viral particles (e.g., rAAV particles) with improved stability and/or improved transduction efficiency by increasing the acetylation and/or deamidation of capsid proteins.
CR20190127A 2016-08-15 2017-08-14 Métodos para detectar aav CR20190127A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662375314P 2016-08-15 2016-08-15
PCT/US2017/046814 WO2018035059A1 (en) 2016-08-15 2017-08-14 Methods for detecting aav

Publications (1)

Publication Number Publication Date
CR20190127A true CR20190127A (es) 2019-06-25

Family

ID=59762045

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20190127A CR20190127A (es) 2016-08-15 2017-08-14 Métodos para detectar aav

Country Status (23)

Country Link
US (5) US11698377B2 (es)
EP (2) EP3851449A1 (es)
JP (3) JP7021191B2 (es)
KR (4) KR102538037B1 (es)
CN (2) CN110168080B (es)
AU (2) AU2017312951B2 (es)
CA (1) CA3033856A1 (es)
CL (2) CL2019000392A1 (es)
CR (1) CR20190127A (es)
CY (1) CY1124364T1 (es)
DK (1) DK3497207T3 (es)
ES (1) ES2863674T3 (es)
HU (1) HUE053747T2 (es)
IL (3) IL312792B1 (es)
MA (1) MA55748A (es)
MX (2) MX2019001938A (es)
NZ (3) NZ751711A (es)
PH (1) PH12019500316A1 (es)
SG (2) SG10201913002QA (es)
TN (1) TN2019000047A1 (es)
TW (2) TWI781953B (es)
WO (1) WO2018035059A1 (es)
ZA (2) ZA201900945B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
US11698377B2 (en) 2016-08-15 2023-07-11 Genzyme Corporation Methods for detecting AAV
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
SI3589730T1 (sl) * 2017-02-28 2024-04-30 The Trustees Of The University Of Pennsylvania Adeno-povezan virus (AAV) clade F vektor in njihova uporaba
MX2020008932A (es) * 2018-02-27 2020-10-01 Univ Pennsylvania Novedosos vectores de virus adenoasociado (aav), vectores de aav que tienen una desamidacion reducida de la capside y usos de estos.
IL276859B2 (en) * 2018-02-27 2025-12-01 Univ Pennsylvania Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor
WO2019173434A1 (en) * 2018-03-06 2019-09-12 Voyager Therapeutics, Inc. Insect cell manufactured partial self-complementary aav genomes
EP4509831A3 (en) * 2018-07-27 2025-03-19 Waters Technologies Corporation Liquid chromatography/mass spectrometry methods for the analysis of polar molecules
US12195745B2 (en) * 2018-08-21 2025-01-14 Massachusetts Eye And Ear Infirmary Compositions and methods for modulating transduction efficiency of adeno-associated viruses
EP3870976B1 (en) 2018-10-25 2023-11-29 Regeneron Pharmaceuticals, Inc. Methods for analysis of viral capsid protein composition
DK3953483T3 (da) * 2019-04-11 2023-12-18 Regenxbio Inc Fremgangsmåder til størrelseskromatografi til karakterisering af sammensætninger af rekombinant adeno-associeret virus
US11841352B2 (en) * 2019-07-31 2023-12-12 Thermo Finnigan Llc Determination and correction of retention time and mass/charge shifts in LC-MS experiments
CA3165911A1 (en) 2020-01-03 2021-07-08 Sarepta Therapeutics, Inc. Methods for analyzing aav capsid proteins
BR112022014852A2 (pt) 2020-01-29 2022-10-11 Genzyme Corp Proteínas modificadas do capsídeo viral adenoassociado para terapia gênica ocular e métodos de uso das mesmas
CN111517359B (zh) * 2020-04-23 2021-08-20 江南大学 一种手性硫化铜超粒子的合成方法
RU2748540C1 (ru) * 2021-02-08 2021-05-26 Автономная некоммерческая образовательная организация высшего образования "Сколковский институт науки и технологий" Способ детектирования вируса SARS-CoV-2 методом масс-спектрометрии
EP4295158A1 (en) * 2021-02-19 2023-12-27 Waters Technologies Corporation Methods for peptide mapping of adeno-associated virus (aav) proteins
WO2022224965A1 (ja) * 2021-04-20 2022-10-27 株式会社ユニバーサル・バイオサンプリング 検体保持カード及びそれを用いた検体の検査方法
EP4370914A1 (en) * 2021-07-12 2024-05-22 Regeneron Pharmaceuticals, Inc. Methods for viral particle characterization using two-dimensional liquid chromatography-mass spectrometry
TW202321691A (zh) * 2021-07-12 2023-06-01 美商再生元醫藥公司 用於分析病毒粒子之線上原生質譜方法
CN113552349B (zh) * 2021-07-30 2022-07-19 上海勉亦生物科技有限公司 Aav蛋白外壳的检测方法
CN118541607A (zh) * 2022-01-06 2024-08-23 富士胶片株式会社 识别蛋白质中的与糖结合的氨基酸部位的方法及试剂盒
WO2024186532A1 (en) * 2023-03-03 2024-09-12 Sartorius Bioanalytical Instruments, Inc. Methods for quantitating viral capsids
US20240418730A1 (en) * 2023-06-19 2024-12-19 Regeneron Pharmaceuticals, Inc. Host cell protein analysis for adeno-associated virus (aav)-based gene therapy
US20250145969A1 (en) * 2023-11-08 2025-05-08 Oxford Biomedica (Us) Llc Deamidation Depleted Adeno-Associated Virus Product

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5540931A (en) 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US6204059B1 (en) * 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
EP0931158A1 (en) 1996-09-06 1999-07-28 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
ATE403715T1 (de) 1999-08-09 2008-08-15 Targeted Genetics Corp Erhöhung der expression einer einzelsträngigen, heterologen nukleotidsequenz von einem rekombinanten viralen vektor durch ausgestaltung der sequenz in einer art und weise, dass basenpaarungen innerhalb der sequenz entstehen
NZ522840A (en) 2000-06-01 2004-12-24 Univ North Carolina A parvovirus vector that carries a duplexed genome resulting in co-packaging of strands of plus and minus polarity tethered together
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
CN103555677B (zh) 2001-11-13 2018-01-30 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
EP1496944B1 (en) 2002-05-01 2008-08-20 University of Florida Research Foundation, Inc. Improved raav expression systems for genetic modification of specific capsid proteins
AU2003294165A1 (en) * 2002-11-22 2004-06-18 Caprion Pharmaceuticals, Inc. Constellation mapping and uses thereof
US7510872B2 (en) 2003-02-26 2009-03-31 Nationwide Children's Hospital Recombinant adeno-associated virus production
ES2521682T3 (es) 2003-05-21 2014-11-13 Genzyme Corporation Procedimientos para producir preparaciones de viriones de AAV recombinantes sustancialmente exentas de cápsidas vacías
EP1486567A1 (en) 2003-06-11 2004-12-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Improved adeno-associated virus (AAV) vector for gene therapy
US9441244B2 (en) * 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
WO2006119432A2 (en) 2005-04-29 2006-11-09 The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes
EP2311967B1 (en) * 2005-10-20 2017-09-20 UniQure IP B.V. Improved AAV vectors produced in insect cells
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
WO2010031865A1 (en) 2008-09-19 2010-03-25 Charitē Universitätsmedizin Berlin Identification and characterisation of recombinant viral gene therapy vectors
EP2396343B1 (en) * 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
HUE040636T2 (hu) 2009-06-16 2019-03-28 Genzyme Corp Javított eljárások rekombináns AAV-vektorok tisztítására
DK2826860T3 (en) 2010-04-23 2018-12-03 Univ Massachusetts CNS targeting AAV vectors and methods for their use
US20130217789A1 (en) * 2010-09-03 2013-08-22 North Carolina Central University Biodegradable liquogel and ph sensitive nanocarriers
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
ES2724800T3 (es) 2011-02-17 2019-09-16 Univ Pennsylvania Composiciones y métodos para alterar la especificidad de tejido y mejorar la transferencia génica mediada por AAV9
US9169299B2 (en) 2011-08-24 2015-10-27 The Board Of Trustees Of The Leleand Stanford Junior University AAV capsid proteins for nucleic acid transfer
RU2683497C2 (ru) 2012-04-18 2019-03-28 Дзе Чилдрен'З Хоспитал Оф Филадельфия Композиция и способы высокоэффективного переноса генов с помощью вариантов капсида aav
US20140017716A1 (en) * 2012-07-11 2014-01-16 Siscapa Assay Technologies, Inc. Proteolytic digestion kit with dried reagents
GB201401707D0 (en) 2014-01-31 2014-03-19 Sec Dep For Health The Adeno-associated viral vectors
KR102572449B1 (ko) 2014-03-10 2023-08-31 유니큐어 아이피 비.브이. 곤충 세포에서 생산된 더욱 향상된 aav 벡터
US11698377B2 (en) 2016-08-15 2023-07-11 Genzyme Corporation Methods for detecting AAV

Also Published As

Publication number Publication date
RU2019107207A (ru) 2020-09-15
JP7021191B2 (ja) 2022-02-16
IL264819B2 (en) 2024-10-01
EP3497207A1 (en) 2019-06-19
CN118688363A (zh) 2024-09-24
JP2019533803A (ja) 2019-11-21
ZA201900945B (en) 2021-06-30
TW202309068A (zh) 2023-03-01
CY1124364T1 (el) 2022-07-22
AU2024200349A1 (en) 2024-02-08
IL312792A (en) 2024-07-01
KR20190039253A (ko) 2019-04-10
WO2018035059A9 (en) 2019-03-14
AU2017312951A1 (en) 2019-04-04
DK3497207T3 (da) 2021-03-22
SG10201913002QA (en) 2020-03-30
CN110168080B (zh) 2024-05-31
IL323969A (en) 2025-12-01
US12123880B2 (en) 2024-10-22
US20240044910A1 (en) 2024-02-08
US20210041451A1 (en) 2021-02-11
MX2019001938A (es) 2019-07-04
KR102922101B1 (ko) 2026-02-03
MX2023009081A (es) 2023-08-08
US11698377B2 (en) 2023-07-11
US12298313B1 (en) 2025-05-13
PH12019500316A1 (en) 2019-08-05
TW201825898A (zh) 2018-07-16
KR20240172773A (ko) 2024-12-10
WO2018035059A1 (en) 2018-02-22
SG11201901221YA (en) 2019-03-28
KR102425289B1 (ko) 2022-07-27
KR20220107327A (ko) 2022-08-02
KR102538037B1 (ko) 2023-05-30
RU2019107207A3 (es) 2021-04-29
NZ791267A (en) 2025-11-28
US20250027951A1 (en) 2025-01-23
NZ791263A (en) 2025-11-28
TWI781953B (zh) 2022-11-01
CN110168080A (zh) 2019-08-23
NZ751711A (en) 2025-11-28
JP2024023460A (ja) 2024-02-21
EP3851449A1 (en) 2021-07-21
IL264819A (es) 2019-04-30
BR112019002934A2 (pt) 2019-05-14
US20250138024A1 (en) 2025-05-01
TN2019000047A1 (en) 2020-07-15
IL312792B1 (en) 2025-11-01
CA3033856A1 (en) 2018-02-22
AU2017312951B2 (en) 2024-02-08
MA55748A (fr) 2022-03-02
JP2022064980A (ja) 2022-04-26
HUE053747T2 (hu) 2021-07-28
IL264819B1 (en) 2024-06-01
ZA202101002B (en) 2024-07-31
KR102738219B1 (ko) 2024-12-05
CL2019000392A1 (es) 2019-05-10
ES2863674T3 (es) 2021-10-11
CL2019002912A1 (es) 2020-03-06
KR20230078834A (ko) 2023-06-02
EP3497207B1 (en) 2021-01-06
US20250147042A1 (en) 2025-05-08

Similar Documents

Publication Publication Date Title
CR20190127A (es) Métodos para detectar aav
MX395524B (es) Proteinas de cápside modificadas para un suministro mejorado de vectores de parvovirus.
MX388331B (es) Variantes de virus adenoasociado y métodos de uso de estas
WO2017066764A3 (en) Modification of n-terminal region of capsid proteins for enhanced properties of adeno-associated viruses
UY36522A (es) Ultracentrifugación analítica para la caracterización de partículas virales recombinantes
EP3790567A4 (en) LIVER-SPECIFIC TROPISM FROM ADENO-ASSOCIATED VIRUSES
CL2017002731A1 (es) Adenovirus oncolítico que codifica una proteína b7
MX384795B (es) Vectores que comprenden secuencias de polinucleotidos rellenadoras/de relleno y metodos de uso.
EP3575398A4 (en) ADENO-ASSOCIATED VIRUS (AAV) CAPSIDE PROTEIN MUTANT
MX2019000882A (es) Metodos de alta recuperacion escalables para una alta produccion de vector viral adenoasociado recombinante (raav) y vectores virales adenoasociados recombinantes (raav) producidos de este modo.
PE20150163A1 (es) Composicion y metodos para una transferencia de genes altamente eficiente usando variantes capside aav
BR112018071180A2 (pt) métodos de reforço potência biológica de baculovirus system-produzido vírus adeno-associado recombinante
MX2016010649A (es) Vector de virus adeno-asociado.
IL292625A (en) Viruses with modified capsid proteins
EP3347460A4 (en) MODIFIED ONCOLYTIC VACCINIA VIRUSES WITH CYTOKIN AND CAR-BOXY-REFERENCE EXPRESSION AND METHOD OF USE THEREOF
CY1124707T1 (el) Συνθεσεις και μεθοδοι για την επαγωγη ενισχυμενης ανοσοαποκρισης με χρηση φορεων ιων poxvirus (ευλογοϊων)
IL282411A (en) Methods for analysis of viral capsid protein composition
MX383506B (es) Parvovirus porcino.
MX378905B (es) Pestivirus.
PH12017501100A1 (en) Recombinant swinepox virus and vaccines
EA201990955A1 (ru) Разработка капсидов aav
BR112019001737A2 (pt) expressão de pten-long com vírus oncolíticos
AR105431A1 (es) Vacunas para enfermedades infecciosas
EA201890595A1 (ru) Онколитический аденовирус, кодирующий белок b7